Matching genetically defined cancer states to drugs that specifically target these states is a principal goal of personalized oncology medicine. In this issue, McMillan et al. show how largescale chemical screening coupled to deep molecular profiling can identify mechanistically diverse druggable vulnerabilities for genetic subtypes of lung cancers.
Cancer research and treatment have greatly benefited from advances in DNA sequencing technologies, which have facilitated the discovery of genetic alterations driving tumorigenesis. Groundbreaking medicines have been developed that target the protein products of some mutated oncogenes-in particular, kinases (Huang et al., 2014) . Many other genetically defined cancers, however, still lack targeted therapies, and some tumor types, including lung cancer, are so heavily mutated that it can be difficult to discern their oncogenic dependencies from DNA sequencing alone, further complicating the path toward therapeutic advances. While molecular biology methods, such as RNA interference and genome editing, have been employed with good success to discover proteins required for the viability of specific subtypes of cancers (Wang et al., 2017) , these approaches often identify proteins that are challenging to target with small-molecule or macromolecular drugs (e.g., transcription factors). Such methods are also weighted toward loss-of-function (LoF) outcomes and therefore less likely to uncover therapeutic opportunities for gain-of-function (GoF) pharmacology.
Small-molecule screening can both complement and address the limitations of genetic approaches by providing a means to directly discover druggable vulnerabilities that reflect not only LoF, but also GoF, and even neo-functional mechanisms of action (Austin et al., 1994; Lu et al., 2014) (Figure 1 ). Key to the success of targeted small-molecule therapies, however, is pinpointing specific tumor types that show maximal drug sensitivity. In this issue of Cell, McMillan et al. (2018) describe a multi-faceted, chemistrycentric screening strategy to identify druggable dependencies associated with specific genetic alterations in a heterogeneous collection of non-smallcell lung cancer (NSCLC) models. This approach began with the rigorous molecular characterization (DNA, mRNA, protein, and metabolite) of a panel of 96 NSCLC cell lines and 4 immortalized human bronchial epithelial cell lines followed by computational clustering to create an ensemble of 15 distinct phenotypic groups, from which representative lines were screened for growth inhibition against a diversity-oriented 200,000 compound library. It is noteworthy that less than 1% of the compounds in the chemical library have known mechanisms of action, distinguishing this study from other cancer cell line screening initiatives that have utilized smaller libraries of chemical probes with established targets/mechanisms (Basu et al., 2013; Iorio et al., 2016; Seashore-Ludlow et al., 2015) , positioning it to discover previously ''undrugged'' targets and pathways. The authors validated their screening and data analysis approach by showing that it properly predicted the sensitivity of tumors with high ALK expression to the ALK inhibitor crizotinib and also tumors with EGFR mutation/amplifications to the EGFR inhibitor erlotinib.
In total, the authors confidently linked an impressive 171 compounds to genomic features of lung cancer that span a broad array of potential druggable vulnerabilities. One such association that constituted a GoF pharmacological outcome was the selective sensitivity to glucocorticoid receptor agonists displayed by NSCLC cells harboring mutations in NOTCH2, an implicated tumor suppressor. These cancer cells were found to have reduced Notch signaling and elevated basal expression levels of the glucocorticoid receptor NR3C1, priming cells to respond to glucocorticoids and undergo subsequent cell-cycle arrest. Compounds also were identified with strong selective toxicity in cells with LoF mutations in TTC21B, a retrograde transport motor for primary cilia, that result in enhanced cilia function. Although TTC21B mutations have not yet been extensively characterized in the context of cancer, primary cilia are known effectors of growth-related pathways (e.g., hedgehog, NFKB, VHL, THF-b), establishing a potential mechanistic basis for TTC21B as a potential vulnerability. Consistent with this hypothesis, the authors proceeded to show that the cilia-disrupting dynein inhibitor, ciliobrevin (Firestone et al., 2012) , impairs the viability of NSCLC cells with TTC21B mutations.
One particularly intriguing outcome of this screen was the strong association of a cohort of active compounds with the expression of drug-metabolizing enzymes, leading the authors to conclude that some cancer vulnerabilities may reflect a state-restricted metabolic activation of inert ''pro-drugs'' into toxic products. The authors, for instance, identified an association of NSCLC lines harboring KRAS/KEAP1 double mutations with sensitivity to the compound SW157765. KRAS is one of the most heavily mutated genes in lung cancers, and KEAP1 is a major regulator of the NRF2 transcription factor, which coordinates antioxidant and cytoprotective transcriptional responses in NSCLC. The authors discovered that sensitivity to SW157765 requires the cytochrome P450 enzyme CYP4F11, a NRF2-induced gene product, which appears to oxidize an internal double bond of SW157765 to create an electrophilic epoxide predicted to engage the proposed mechanistic target-a noncanonical glucose transporter GLUT8 (SLC2A8). The authors show that sensitivity to GLUT8 inhibition reflects a selective metabolic dependency on downstream serine biosynthesis stemming from combined KRAS/NRF2 pathway activation.
Overall, this study highlights the power of combining deep molecular profiling and chemical screening to identify druggable vulnerabilities for subtypes of genetically heterogeneous cancers. That several of the hit compounds appear to act by GoF or neo-functional mechanisms highlights the distinctive value of chemical screening for the discovery of cancer vulnerabilities. Of course, whether such vulnerabilities-which, in some cases, may constitute proteins that are not themselves required for cancer growth or survival-can be exploited to furnish durable therapies remains an important open question. Further work will also be required to understand the clinical translatability of the findings, although the authors do note that many of the identified vulnerabilities in NSCLC lines are present in primary lung tumors of the corresponding genetic state. More generally, this tour-de-force study, along with other emerging chemical proteomic strategies (Bar-Peled et al., 2017) , offers a compelling template to fulfill the promise of ''chemistry-first'' approaches for the discovery of novel, druggable vulnerabilities matched to molecularly annotated cancer states that lack targeted therapies.
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